Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update

被引：34
|
作者：
Giordano, Sharon H. [1 ]
Freedman, Rachel A. [2 ]
Somerfield, Mark R. [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 03期
关键词：
D O I：
10.1200/JCO.21.02677
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
引用
收藏
页码：307 / +
页数：4
相关论文
共 50 条
  • [21] Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
    Visvanathan, Kala
    Fabian, Carol J.
    Bantug, Elissa
    Brewster, Abenaa M.
    Davidson, Nancy E.
    DeCensi, Andrea
    Floyd, Justin D.
    Garber, Judy E.
    Hofstatter, Erin W.
    Khan, Seema A.
    Katapodi, Maria C.
    Pruthi, Sandhya
    Raab, Rachal
    Runowicz, Carolyn D.
    Somerfield, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (33) : 3152 - +
  • [22] Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
    Kalemkerian, Gregory P.
    Khurshid, Humera
    Ismaila, Nofisat
    Systemic Therapy for Small Cell Lung Cancer Guideline Expert Panel
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (01)
  • [23] Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy A Prespecified Analysis of the monarchE Randomized Clinical Trial
    Martin, Miguel
    Hegg, Roberto
    Kim, Sung-Bae
    Schenker, Michael
    Grecea, Daniela
    Angel Garcia-Saenz, Jose
    Papazisis, Konstantinos
    Ouyang, Quchang
    Lacko, Aleksandra
    Oksuzoglu, Berna
    Reeves, James
    Okera, Meena
    Testa, Laura
    Shimizu, Chikako
    Denduluri, Neelima
    Adamchuk, Hryhoriy
    Dakhil, Shaker
    Wei, Ran
    Forrester, Tammy
    Fernandez, Maria Munoz
    Zimmermann, Annamaria
    Headley, Desiree
    Johnston, Stephen R. D.
    JAMA ONCOLOGY, 2022, 8 (08) : 1190 - 1194
  • [24] Abemaciclib combined with adjuvant endocrine therapy in patients from Asia with high risk early breast cancer: monarchE
    Yap, Y-S.
    Kim, S-B.
    Chiu, J. W. Y.
    Lim, E.
    Broom, R.
    Liu, Z.
    Sagara, Y.
    Chao, T-Y.
    Sherwood, S.
    McNaughton, R. E.
    Wei, R. J.
    Toi, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S41 - S42
  • [25] Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update Summary
    Fabian, Carol J.
    Visvanathan, Kala
    Somerfield, Mark R.
    JOURNAL OF ONCOLOGY PRACTICE, 2019, 15 (11) : 607 - +
  • [26] Optimal adjuvant endocrine therapy for early breast cancer
    Stuart-Harris, Robin
    Davis, Alison
    WOMENS HEALTH, 2010, 6 (03) : 383 - 398
  • [27] Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update
    Korde, Larissa A.
    Somerfield, Mark R.
    Hershman, Dawn L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (15) : 1696 - +
  • [28] Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A
    Vikas, Praveen
    Korde, Larissa A.
    Somerfield, Mark R.
    Hershman, Dawn L.
    JCO ONCOLOGY PRACTICE, 2022, 18 (09) : 649 - +
  • [29] Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
    Tung, Nadine M.
    Zakalik, Dana
    Somerfield, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2959 - +
  • [30] Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A
    Moy, Beverly
    Wolff, Antonio C.
    Rumble, R. Bryan
    Allison, Kimberly H.
    Carey, Lisa A.
    JCO ONCOLOGY PRACTICE, 2023, 19 (08) : 547 - +
12345